A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .

Authors

A. Sandler

Oregon Health & Science University, Portland, OR

A. Sandler , J. H. Schiller , V. Hirsh , L. V. Sequist , J. Soria , J. Von Pawel , Q. Wang , A. U. Pande , B. E. Schwartz , E. G. Garmey , I. Gorbatchevsky , G. Scagliotti

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.

First Author: Koichi Azuma

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS^G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.

First Author: Federico Cappuzzo

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.

First Author: Yuankai Shi

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).

First Author: Hongyun Zhao